Aim: To study treatment outcome in carcinoma urinary bladder patients who underwent chemoradiation. Methods: A single institutional study of patients of muscle invasive bladder carcinoma treated with transurethral resection of bladder tumour (TURBT) followed by chemoradiation from January 2014–january 2019 where retrospectively evaluated for response after treatment. Results: A total of 24 patients were treated from 2014–2019. Age group of 46–84years, mean age 65year. 20 patients were males and 4 female patients. All 24 patients underwent TURBT and radiation therapy. Radical radiation was changed to palliative radiation in 2 patients (due to deteriorating general condition and progressive disease). Rest of 22 patients received concurrent chemoradiation with average dose of 60–66 Gy in 33 fractions, 2Gy per dose fraction. Of this 24 patients, 3 patients expired during the course of treatment, (1patient had seizure disorder and developed aspiration pneumonia,1 due to cardiac arrest and renal failure due volume over load, other patient had sudden cardiac arrest). Complete response was seen in 9 patients, 3 patients had residual disease, 5 patients had progressive disease and 4patients were lost to follow up. Grade 1–3 toxicities were seen during treatment and no grade 4 acute or late toxicity was encountered. Conclusion: Most of the patients referred to radiation were elderly patients with multiple comorbidities with poor performance status. Our results demonstrate that radiation dose above 60Gy is associated with improved bladder preserved overall survival rates. Overall, concurrent chemoradiation in muscle invasive bladder cancer has demonstrated reasonable efficacy.